BEAM Profile
Beam Therapeutics Inc. (BEAM) is a biotechnology company headquartered in Cambridge, Massachusetts, USA. The company is focused on developing precision genetic medicines based on its proprietary base editing technology platform.
Beam's lead product candidate is BEAM-101, an investigational therapy for the treatment of sickle cell disease and beta-thalassemia. BEAM-101 is designed to edit the DNA of patients' red blood cells to increase the expression of fetal hemoglobin, which can help alleviate the symptoms of these diseases. BEAM-101 is currently being evaluated in a Phase 1/2 clinical trial, and the company is also planning to initiate a Phase 2a clinical trial in 2022. Beam is also developing other product candidates for the treatment of various genetic diseases, including BEAM-201 for the treatment of certain types of cancers.
In December 2021, Beam announced positive interim data from its Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell disease and beta-thalassemia. The data showed that BEAM-101 was generally well-tolerated and demonstrated encouraging signs of clinical activity, including an increase in fetal hemoglobin levels and a reduction in the frequency of vaso-occlusive crises in sickle cell disease patients. The company plans to continue the development of BEAM-101 and expects to initiate additional clinical trials in the coming months.
As of September 30, 2021, Beam had cash, cash equivalents, and marketable securities of $1.2 billion. The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.
Beam's stock is listed on the NASDAQ stock exchange and has a market capitalization of approximately $7.6 billion as of February 21, 2023.
|
